2,173 research outputs found
Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma.
No full textinfo:eu-repo/semantics/publishe
Il progetto performativo
No full textPartendo dall'analisi linguistica degli enunciati performativi e dalle sue implicazioni logico-filosofiche, il contributo propone una declinazione pratico-strumentale del termine "performativo", volta ad identificare possibili modalità progettuali in ambito urbanistico e paesaggistico
Fertility preservation in BRCA-mutated breast cancer patients
No full textA possible side effect of anticancer treatments in premenopausal women is the occurrence of premature ovarian failure and subsequent infertility. The inheritance of a deleterious genetic mutation in the BRCA1 or 2 genes generates the hereditary breast and ovarian cancer syndrome. Additional fertility counseling for breast cancer patients with BRCA mutations is warranted to educate them about the available fertility preservation options in the context of their unique concerns (i.e., prophylactic gynecologic surgery, pre-implantation genetic diagnosis and risk of developing long-term treatment-related premature ovarian failure). In this report we discuss the available options for fertility preservation in women with breast cancer, with a particular focus on the specific issues in breast cancer patients with BRCA mutations
Cyclophosphamide-free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women with Breast Cancer
No full text
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy
No full textSCOPUS: le.jinfo:eu-repo/semantics/publishe
Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer
No full textPURPOSE OF REVIEW: This manuscript aims at providing an updated overview on the role of adding ovarian function suppression to tamoxifen or an aromatase inhibitor as adjuvant endocrine therapy in premenopausal women with estrogen receptor-positive early breast cancer. RECENT FINDINGS: Until recently, tamoxifen alone was the only recommended adjuvant treatment option for premenopausal women with estrogen receptor-positive disease. However, recent important evidence has contributed to significantly modify the endocrine treatment landscape in this setting. SUMMARY: With the only exception of patients with low-risk clinical-pathological features characterized by excellent survival outcomes with tamoxifen alone, the use of ovarian function suppression is to be considered standard of care for most of premenopausal women with estrogen receptor-positive disease. Regarding the choice of its best partner as endocrine agent, the available data suggest that the higher the risk of disease recurrence the larger benefit can be observed with a more profound estrogen deprivation that can be obtained with ovarian function suppression and an aromatase inhibitor as compared to ovarian function suppression and tamoxifen. Despite the significant improvement in our understanding on the role of ovarian function suppression in this setting, several unanswered questions remain and further research efforts are needed in the field.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?
No full textSCOPUS: re.jinfo:eu-repo/semantics/publishe
- …
